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Abstract
Background: Considerable evidence has accumulated that multiple viruses, bacteria, and protozoa manipulate interleukin-
10 (IL-10)-mediated signaling through the IL-10 receptor (IL-10R) in ways that could enable establishment of a persistent
microbial infection. This suggests that inhibition of pathogen targeting of IL-10/IL-10R signaling could prevent microbial
persistence. Human cytomegalovirus (HCMV) and rhesus cytomegalovirus (RhCMV) express a viral interleukin-10 (cmvIL-10
and rhcmvIL-10, respectively) with comparable immune modulating properties in vitro to that of their host’s cellular IL-10
(cIL-10). A prior study noted that rhcmvIL-10 alters innate and adaptive immunity to RhCMV in vivo, consistent with a central
role for rhcmvIL-10 during acute virus-host interactions. Since cmvIL-10 and rhcmvIL-10 are extremely divergent from the
cIL-10 of their respective hosts, vaccine-mediated neutralization of their function could inhibit establishment of viral
persistence without inhibition of cIL-10.
Methods and Findings: As a prelude to evaluating cmvIL-10-based vaccines in humans, the rhesus macaque model of
HCMV was used to interrogate peripheral and mucosal immune responses to rhcmvIL-10 in RhCMV-infected animals. ELISA
were used to detect rhcmvIL-10-binding antibodies in plasma and saliva, and an IL-12-based bioassay was used to quantify
plasma antibodies that neutralized rhcmvIL-10 function. rhcmvIL-10 is highly immunogenic during RhCMV infection,
stimulating high avidity rhcmvIL-10-binding antibodies in the plasma of all infected animals. Most infected animals also
exhibited plasma antibodies that partially neutralized rhcmvIL-10 function but did not cross-neutralize the function of
rhesus cIL-10. Notably, minimally detectable rhcmvIL-10-binding antibodies were detected in saliva.
Conclusion: This study demonstrates that rhcmvIL-10, as a surrogate for cmvIL-10, is a viable vaccine candidate because (1)
it is highly immunogenic during natural RhCMV infection, and (2) neutralizing antibodies to rhcmvIL-10 do not cross-react
with rhesus cIL-10. Exceedingly low rhcmvIL-10 antibodies in saliva further suggest that the oral mucosa, which is critical in
RhCMV natural history, is associated with suboptimal anti-rhcmvIL-10 antibody responses.
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Introduction
Human cytomegalovirus is well recognized as a clinically
relevant pathogen in those with immature or compromised
immune systems, particularly congenitally infected fetus/newborns
and immunosuppressed transplant recipients. Because of the
pathogenic potential of HCMV in these and other populations,
there have been four decades of calls to develop a vaccine that
confers protective efficacy against HCMV infection and disease
[1–5]. Primary vaccine research has focused on those HCMV
proteins encoding epitopes for either neutralizing antibodies
(glycoprotein B-gB) or strong cellular immune responses (phos-
phoprotein 65 and immediate early-1), based on humoral and
cellular immune correlates of protection against congenital
infection and transplantation-associated HCMV disease, respec-
tively [6,7]. Two vaccine trials based on recombinant gB
vaccination in seronegative pregnant women and seronegative
renal transplant recipients demonstrated partial, but incomplete,
protection. One possibility for boosting protective efficacy beyond
that observed in the gB trials is to include additional HCMV
antigens to broadly target vulnerable components of viral
replication. Additionally, an important related issue is whether
there is a need to direct the vaccine immune responses to mucosal
sites to maximize the immediacy of antiviral responses that prevent
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infection. Our current study in the rhesus macaque model of
HCMV infection was initiated to begin to address these two issues
of HCMV vaccine design based on the following considerations.
HCMV immune modulating proteins that disrupt host cell
functions, including antigen presentation, signaling, trafficking,
activation, and metabolism, have not been evaluated as vaccine
candidates. A large percentage of the coding capacity of the
HCMV genome is devoted to these proteins, and in vitro studies
strongly suggest that HCMV immune modulating proteins
collectively could skew host immunity during critical junctures of
HCMV infection in vivo. Limited studies have observed cellular
immune responses specific to presumptive HCMV immune
modulating proteins, including those that disrupt MHC class I
antigen presentation (US2, US3, US6, US11), and those that
inhibit NK function (UL16, UL18) [8,9]. Antibody responses have
also been detected against UL111A (cmvIL-10) in some HCMV-
infected individuals [10]. One group profiling HCMV T cell
responses noted that, based on the in vitro phenotype of the
immune modulating proteins and their potential role in vivo,
‘‘Future investigations will need to assess the levels of protection
afforded by responses directed toward these epitopes’’ [8].
Mucosal surfaces are the sites of both primary infection and
reinfection. Analytic modeling of published congenital transmis-
sion rates has led to the conclusion that ,75% of congenital
infections in the United States occur in women with preconcep-
tional immunity to HCMV [11]. The study did not determine
whether maternal-to-fetal transmission was the result of maternal
reactivation of preexisting virus or reinfection with a horizontally
transmitted virus. Based on multiple studies demonstrating
reinfection of seroimmune pregnant women, including in popu-
lations with universal seroprevalence, it is clear that prior
immunity is only partially protective against reinfection [12–19].
A salient point of these studies is that HCMV reinfection in these
instances was the result of mucosal exposure to horizontally
acquired virus, implying that mucosal antiviral immune responses
were insufficient to contain viral reinfection locally.
With the long-term goal of testing in vivo the concept of immune
modulating proteins as vaccine candidates, immune responses to
rhcmvIL-10 (RhUL111A) were evaluated in healthy RhCMV-
infected rhesus macaques persistently infected with wild-type
RhCMV. Studies have shown that rhcmvIL-10 plays a dynamic
role in viral immune modulation, mimicking cellular IL-10
functions in vitro and altering innate and adaptive immune
responses to viral antigens in vivo [20]. Microbial manipulation
of IL-10 appears to be a common feature of many persistent
viruses (e.g., murine CMV, LCMV, hepatitis B and C viruses),
bacteria (e.g., Chlamydia trachomatis, and Listeria monocytogenes), and
protozoa (e.g., Leishmania and Plasmodium species) [21–36], and
commensal bacteria [37–39]. Thus, there is extensive precedent to
focus on rhcmvIL-10 and cmvIL-10 as central players in primate
CMV natural history. The potential viability of using rhcmvIL-10
in a vaccine was recently described for rhcmvIL-10 [40].
Structural biology was used to engineer biologically inactive
mutants of rhcmvIL-10 that do not bind to the IL-10 high-affinity
receptor and, therefore, lack wild-type functional activity. To
provide a foundation for evaluating the immunogenicity of non-
functional versions of rhcmvIL-10 in RhCMV-uninfected animals,
peripheral and mucosal immune responses to wild-type rhcmvIL-
10 were surveyed in RhCMV-infected juvenile and adult rhesus
macaques.
Results
rhcmvIL-10-binding antibodies in RhCMV-infected
monkeys
A rhcmvIL-10 ELISA was developed to characterize the
kinetics and magnitude of rhcmvIL-10-specific binding antibodies
in macaques naturally exposed to RhCMV circulating in outdoor-
housed cohorts (see Materials and Methods for details). Plasma
samples from outdoor-housed rhesus macaques, which were
confirmed to be either RhCMV seropositive (N=54) or seroneg-
ative (N=35) by an ELISA using RhCMV-infected cell extract as
antigen were randomly chosen and screened by ELISA for the
presence of rhcmvIL-10 binding antibodies. All RhCMV anti-
body-positive macaques were positive for rhcmvIL-10-binding
antibodies, while all RhCMV antibody-negative samples were also
negative for rhcmvIL-10 antibodies (p,0.0001) (Fig. 1). rhcmvIL-
10-binding antibody titers in the RhCMV antibody-positive
population ranged from 3–24 relative units (RU) with a median
of 11.9 RU. When rhcmvIL-10 antibody titers were stratified by
the age of the animal, (#1, 5–10, and .13 years, corresponding to
infant (N=17), adult (N=22), and aged (N=15) animals,
respectively), significantly higher rhcmvIL-10-specific titers were
detected in the infants, compared to the adult and aged groups
(p,0.001, p,0.01 respectively) (Fig. 2A). The rhcmvIL-10 titers in
the adult and aged animals were indistinguishable. Previous
seroepidemiological studies have demonstrated that there is 50%
seroconversion to RhCMV infection by 6 months of age and
complete seroconversion around 1 year in outdoor, group-housed
macaques, similar to those included in this study [41]. Thus, the
adult and aged animals had, most probably, been infected long-
term (.4–.12 years) with RhCMV. The relative increased
antibody responses to rhcmvIL-10 in the infants did not appear to
be specific to this particular viral protein. A similar age-related
pattern of seroreactivity was observed when an antigen prepara-
tion, consisting of a total protein lysate of RhCMV-infected cells,
was used instead (data not shown). There was a strong correlation
between rhcmvIL-10 titers and RhCMV antibody titers (Pearson,
r=0.6176, p,0.0001) (Fig. 2B), indicating that the magnitude of
rhcmvIL-10 antibody titers reflected the magnitude of antibody
titers to total RhCMV antigens.
Avidity of rhcmvIL-10 antibodies
The binding strength of antibodies was evaluated for 50
RhCMV-positive macaques using an ELISA avidity assay with a
6 M Urea wash. All RhCMV-infected animals exhibited high
avidity indices to rhcmvIL-10, ranging from 0.63 to 0.96 with an
average of 0.83 (standard deviation=0.076) (Fig. 3). These results
were consistent with what has previously been found in overall
RhCMV antibody avidity [42]. No differences in avidity were
detected between the age groups.
rhcmvIL-10-neutralizing antibody titers
rhcmvIL-10 antibody responses in plasma were quantified by an
in vitro assay to determine if rhcmvIL-10-binding antibodies also
neutralized its functional activity. Plasma samples from RhCMV-
immune animals were evaluated for the ability to neutralize
rhcmvIL-10-mediated responses in activated peripheral blood
mononuclear cells (PBMC). In brief, the assay compared the level
of IL-12 synthesized by lipopolysaccharide (LPS)-activated PBMC
following incubation with either rhcmvIL-10 diluted in rhesus
plasma or plasma alone (Fig. 4). Preliminary assays verified that
LPS-stimulated PBMC secreted high amounts of IL-12 (an
average of 1.5 ng/2610
5 cells), which was abrogated when the
cells were pre-treated with rhcmvIL-10 (data not shown). Since
Immunogenicity of the RhCMV-Encoded Viral IL-10
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PBMC, antibody-mediated neutralization of rhcmvIL-10 activity
was measured by increased levels of IL-12 production following
incubation of LPS-activated PBMC with rhcmvIL-10. If a plasma
sample lacked rhcmvIL-10 neutralizing antibodies, IL-12 expres-
sion would not be restored. Based on these results, IL-12 induction
was used to quantify the ability of rhcmvIL-10 antibodies to bind
to and neutralize rhcmvIL-10 activity. Plasma samples from 26
seropositive and 9 seronegative rhesus macaques were selected
from the pool of those previously assayed by the rhcmvIL-10-
binding ELISA and assessed for the ability to neutralize rhcmvIL-
10 activity (Fig. 4). RhCMV seropositive animals exhibited a wide
range of neutralizing activity (0–100% IL-12 induction restored)
with a median at 15.9% IL-12 induction restored (Fig. 4A). No
neutralization of rhcmvIL-10 was detected using plasma from
RhCMV-uninfected monkeys. rhcmvIL-10 neutralizing titers
exhibited a positive correlation with rhcmvIL-10 antibody titers
(Fig. 4B; r=0.8292, p,0.0001). Infants showed slightly higher
rhcmvIL-10 neutralizing titers than adults (data not shown),
consistent with the higher rhcmvIL-10 antibody titers observed in
this age group (Fig. 2B).
Mucosal Antibody Levels
Since HCMV infection and shedding occur at mucosal surfaces,
local immune responses in the mucosa are likely to be important
for mediating protection against reinfection and in determining
the frequency and magnitude of shedding. Saliva samples from 20
RhCMV seropositive juveniles (2–4 years), 20 RhCMV seropos-
itive adults (.10 years old), and 10 RhCMV seronegative
macaques were analyzed by ELISA for IgG responses specific to
RhCMV and rhcmvIL-10. Saliva IgG was evaluated to provide a
surrogate measure of tissue levels of rhcmvIL-10 NAb either
secreted by plasma cells in the submucosa or transudated from
plasma. IgA levels were not analyzed since both rhcmvIL-10 and
cmvIL-10 are secreted proteins [20,43]. In addition, there is no
evidence that cmvIL-10 is present in the HCMV virion [44].
Saliva antibody titers to rhcmvIL-10 and RhCMV were exceed-
ingly low in the RhCMV seropositive animals (Figs. 5A and 5B),
yet a threshold for determining a positive response was established
Figure 1. rhcmvIL-10 antibody seroprevalence in rhesus
macaques. Plasma samples from macaques confirmed positive or
negative for RhCMV (54 RhCMV seropositive, 35 seronegative) were
screened for the presence of rhcmvIL-10 antibodies by rhcmvIL-10
ELISA. RhCMV seropositive samples had significantly higher rhcmvIL-10
antibody levels than seronegative samples (p,0.0001; two-tailed
unpaired student’s t-test) with a range of 3 to 24 Relative Units (RU).
The line represents the median for the group.
doi:10.1371/journal.pone.0037931.g001
Figure 2. rhcmvIL-10 antibody response. (A) An age comparison
of rhcmvIL-10 responses in 54 macaques seropositive for RhCMV
stratified into 3 age groups; infant (#1 year), adult (5–10 years) and
aged ($13 years). The infants had significantly higher antibody titers
than the adults and aged (p,0.01, p,0.05 respectively). Statistical
analysis between age groups was done using Kruskal-Wallis test with
Dunn’s Multiple Comparison. There was no significant difference
between the adult and aged animal groups. (B) Linear regression
analysis of RhCMV antibodies and rhcmvIL-10 antibodies from 53 rhesus
macaques reported in relative units (RU). There was a significant
correlation between total RhCMV titers and rhcmvIL-10 antibody titers
(Pearson r=0.6176, p,0.0001) with RhCMV antibody titers being
significantly predictive of rhcmvIL-10 antibody production.
doi:10.1371/journal.pone.0037931.g002
Immunogenicity of the RhCMV-Encoded Viral IL-10
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considered positive if the optical density (OD) equaled or exceeded
the mean OD of the seronegative animals plus 3 standard
deviations of the mean. Small differences were noted between the
juvenile and adult responses in saliva (Figs. 5C and 5D). Whereas
rhcmvIL-10 responses were slightly higher in juveniles and
RhCMV-specific responses were higher in adults, the differences
were not statistically significant. Notably, only 50% of the juveniles
had detectable RhCMV antibodies in saliva, compared with 85%
of adults with detectable antibodies in saliva. Based on the
dilutions used for the saliva and plasma, and the ELISA responses,
antibody levels in saliva were ,0.025% of those found in their
corresponding plasma samples (Fig. 5 and data not shown). Studies
in humans indicate that saliva IgG levels are ,0.1% of IgG titers
in plasma [45–47]. The IgG responses in saliva were directly
correlated with those in plasma for both rhcmvIL-10 (r=0.5291,
p=0.0054) and RhCMV antigens (r=0.5881, p=0.0016) (Fig. 6).
These results were consistent with previous studies demonstrating
that mucosal IgG is primarily derived from transudated plasma
IgG [48–50].
Absence of cross-reactive neutralization to rhesus cIL-10
Considering the extensive sequence divergence between
rhcmvIL-10 and rhesus cIL-10 (25% amino acid identity), there
is little likelihood that antibodies specific to rhcmvIL-10 would
cross-react with epitopes (linear or conformational) within cIL-10.
Further, since RhCMV infection is subclinical in rhesus macaques,
there is no clinical evidence consistent with development of
autoimmune antibodies to rhesus cIL-10 coincident with devel-
opment of antibodies to rhcmvIL-10. To rule out the hypothetical
possibility of cross-reactivity, such as those directed at potential
conformational epitopes, rhcmvIL-10 neutralization assays were
performed to determine whether plasma samples that neutralized
rhcmvIL-10 similarly neutralized the immunosuppressive activity
of rhesus cIL-10 on LPS-activated PBMC. Plasma from six
RhCMV-infected macaques that neutralized rhcmvIL-10 activity
from 60–100% had undetectable neutralizing activity against
rhesus cIL-10 (Fig. 7). IL-12 remained undetectable in the
supernatant of LPS-activated PBMC when co-incubated with
cIL-10 and plasma from these same animals. These results strongly
indicate that antibodies specific to rhcmvIL-10 generated during
the course of RhCMV infection do not cross-react with
endogenous cIL-10.
rhcmIL-10-specific T-cell responses
To evaluate the prevalence and magnitude of the cellular
response to rhcmvIL-10, FLOW cytometry was used to determine
the frequency and magnitude of rhcmvIL-10-specific T-cell
responses. PBMC from 23 out-door housed, RhCMV-infected
animals were stimulated with either total RhCMV antigen or
Figure 3. rhcmvIL-10 antibody avidity. Plasma samples from
RhCMV-infected animals #1 (N=17), 5–10 (N=17), and $13 (N=16)
years of age were assayed for avidity of rhcmvIL-10 antibodies (see
Materials and Methods). The average avidity ratio for each group was
0.82 (#1 year), 0.84 (5–10 years), and 0.84 ($13 years). There was no
significant difference between age groups.
doi:10.1371/journal.pone.0037931.g003
Figure 4. rhcmvIL-10 antibodies neutralized rhcmvIL-10 activ-
ity in stimulated PBMC. rhcmvIL-10 neutralization was determined
by incubating LPS-stimulated PBMC with either rhcmvIL-10 and RhCMV
seropositive plasma, or rhcmvIL-10 only. The % difference of PBMC IL-12
secretions in the rhcmvIL-10/ plasma versus plasma only (measured by
ELISA) was termed ‘‘% IL-12 induction restored’’. (A) Seropositive plasma
sample neutralization of rhcmvIL-10 resulted in a range of 0–100% IL-12
induction restored with a significant difference between the RhCMV
seropositive and seronegative samples (p=0.0083; two-tailed student’s
t-test). The relative relation between %IL-12 restored and strength of
NAB is shown on the right. (B) % IL-12 induction restored was found to
be directly correlated to rhcmvIL-10 antibody titers (measured in RU) in
rhesus macaque seropositive plasma (Pearson r=0.8292. p,0.0001).
doi:10.1371/journal.pone.0037931.g004
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rhcmvIL-10 (termed M1 and M2) [40] were used to avoid the
immunosuppressive effects of wild-type rhcmvIL-10. Only 22%
(N=5 animals) of RhCMV-infected animals had detectable
rhcmvIL-10-specific T cell responses (Table 1). 13% (N=3)
exhibited a CD4
+/IFN-c
+ T-cell response, and 8% (N=2) had a
CD8
+ T-cell response (IFN-c). As a confirmation that the
population had RhCMV-specific cellular responses, PBMC were
also stimulated with heat-inactivated RhCMV virion. 96% of
animals (N=22) had a RhCMV-specific CD4
+/IFN-c
+ T-cell
response while 30% had a CD8
+/IFN-c
+. In sum, while rhcmvIL-
10 stimulates antibody responses in all RhCMV-infected animals,
only a minority of infected animals developed detectable cellular
responses.
Discussion
Multiple studies have documented that HCMV can reinfect
immune competent individuals with prior HCMV infection [11–
Figure 5. Analysis of mucosal IgG. Saliva samples from RhCMV seropositive and seronegative animals were analyzed by ELISA for IgG responses
to rhcmvIL-10 (A) and RhCMV (B) (one-tailed student’s t-test). RhCMV seropositive animals were stratified by age as either juvenile (2–4 years) or aged
($13 years) for IgG responses to rhcmvIL-10 (C) and RhCMV (D), in comparison to responses in RhCMV seronegative animals. The dashed line is the
cut-off for samples to be considered positive. Statistical analysis between age groups was done using Kruskal-Wallis test with Dunn’s Multiple
Comparison.
doi:10.1371/journal.pone.0037931.g005
Figure 6. Correlation of saliva IgG and plasma IgG responses to rhcmvIL-10 and RhCMV. The optical density (OD) of the saliva and plasma
IgG responses to rhcmvIL-10 (left) and RhCMV antigens (right) are presented.
doi:10.1371/journal.pone.0037931.g006
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women that were longitudinally evaluated developed novel
HCMV antibody specificities, equivalent to an annual rate of
HCMV reinfection of 10% [53]. This is particularly remarkable
because ,10% of memory T cells in healthy long-term HCMV
carriers are HCMV-specific, and neutralizing antibodies are
generated against multiple viral glycoproteins [9,54–58]. Taken
together, studies of reinfection indicate a viral mechanism to
surmount preexisting immune memory to initiate a new infection,
which implies that infection of an immune host may be
independent of whether antiviral immunity is from prior infection
or prior vaccination.
Accordingly, one strategy to increase vaccine-mediated protec-
tive efficacy beyond that afforded by gB alone would be to target
the HCMV mechanisms responsible for immune evasion, partic-
ularly those that are operative during the initial virus-host
interactions. Multiple in vitro and in vivo studies of cmvIL-10 and
rhcmvIL-10 support a model in which the viral ortholog of cIL-10,
expressed at the site of infection, subverts local and systemic
immunity to enable dissemination of progeny virions to distal sites
[20,59–66]. This study demonstrates that rhcmvIL-10 is highly
immunogenic during natural RhCMV infection, and infection-
generated antibodies that neutralize rhcmvIL-10 function are
specific to the viral IL-10 ortholog; there is no evidence that there
is any cross-reactivity with rhesus cIL-10. By extension, rhcmvIL-
10 vaccine-induced neutralizing antibodies in a naı ¨ve host should
not cross react with cIL-10. Since immunization with a functional
version of rhcmvIL-10 could skew immune responses because of
the immunosuppressive properties of rhcmvIL-10, an alternative
vaccine strategy has recently been described [67]. Two mutated
versions of rhcmvIL-10 (M1 and M2) were generated, each
containing two point mutations within the IL-10R binding site.
Neither mutated version of rhcmvIL-10 bound soluble IL-10R,
and neither had functional activity on activated PBMC. In
addition, immunization of RhCMV-infected monkeys with M1
and M2 boosted preexisting rhcmvIL-10-binding and neutralizing
antibodies. This proposed vaccine approach for rhcmvIL-10, and
by extension cmvIL-10, takes advantage of the extreme sequence
divergence between rhcmvIL-10 and cmvIL-10 from the cIL-10 of
their macaque and human host, respectively [68]. While primate
cIL-10 proteins share .95% identity, the viral IL-10 orthologs are
nearly as divergent from each other (31% identity) as they are from
the cIL-10 of their host (25–27%). This kind of approach is not
likely to work for the Epstein-Barr Virus IL-10 protein (ebvIL-10;
Accession # P03180), which retains 92% identity with human
cIL-10 (P22301). Antibodies that bind human cIL-10 also bind
Figure 7. Absence of cross-reactivity of rhcmvIL-10 neutralizing antibodies to rhesus cellular IL-10 (cIL-10). Plasma from six RhCMV-
infected (Mmu 1–Mmu 6) monkeys and one RhCMV-uninfected monkey (Mmu 7) were assayed for the ability to neutralize functional activity of
rhcmvIL-10 (open column) and cIL-10 (filled column). Plasma from Mmu 1–Mmu 6 neutralized rhcmvIL-10 functionality but had no neutralization of
cIL-10. Media: no plasma was added to the reaction.
doi:10.1371/journal.pone.0037931.g007
Table 1. IFNc responses in CD4
+ and CD8
+ T cells from 24 RhCMV-infected macaques following coincubation with either RhCMV
or rhcmvIL-10 M1/M2 antigens.
CD4 CD8
Antigen
% of animals with IFNc
+
CD4
+ T cells (#)
Mean Percentage of IFNc
+
CD4
+ T cells (SD)
% of animals with
IFNc
+ CD8
+ T cells (#)
Mean Percentage of IFNc
+
CD8
+ T cells (SD)
RhCMV 96 (22) 0.29 (0.15) 30 (7) 0.06 (0.04)
rhcmvIL-10M1/M2 13 (3) 0.04 (0.017) 8 (2) 0.015 (0.002)
doi:10.1371/journal.pone.0037931.t001
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same study also demonstrated that monoclonal antibodies to
cmvIL-10 do not bind human cIL-10 or ebvIL-10. HCMV also
expresses a Latency Associated cmvIL-10 (LAcmvIL-10) that is the
result of translation of a partially spliced transcript of cmvIL-10
[70]. It is not known at this time whether a comparable
LArhcmvIL-10 is expressed in RhCMV-infected cells. Since
evidence suggests that LAcmvIL-10 does not bind to IL-10R1
[71], it is probable that antibodies that neutralize cmvIL-10
engagement of IL-10R1 would likely not neutralize LAcmvIL-10,
although this remains to be verified.
The characterization of rhcmvIL-10 immune responses in
RhCMV-infected macaques provides two important benchmarks
for vaccination of naı ¨ve macaques with non-functional versions of
rhcmvIL-10: generation of (1) high titers of plasma antibodies that
neutralize rhcmvIL-10 function, and (2) more robust mucosal anti-
rhcmvIL-10 responses. This latter point is a reflection of the
importance of mucosal surfaces in HCMV and RhCMV natural
history. Since the overall rate of congenital infection is ,0.6%
[72], the overwhelming preponderance of primary infections
results from horizontal transmission of HCMV in bodily fluids of
an infected person to an epithelial cell surface, such as the oral and
genital mucosa, of an uninfected recipient. These also serve as
portals for reinfection of immune hosts, and as sources of viral
shedding in long-term infected individuals. An ideal vaccine would
absolutely contain virus locally after mucosal exposure and block
dissemination to such distal sites as the maternal-fetal interface.
The absence of complete protection in the gB vaccine trials and
the ability of HCMV to reinfect immune hosts implicate a failure
of local immunity to contain ‘‘challenge’’ virus. Consequently,
boosting mucosal immune responses could increase the protective
efficacy of vaccine-generated immunity. Since antibody responses
that neutralize rhcmvIL-10 function are linearly related to the
binding antibody responses, the minimally detectable rhcmvIL-10-
binding antibodies in saliva imply that local antibody responses at
the oral mucosa would be insufficient to neutralize soluble
rhcmvIL-10 after exposure to a reinfecting virus. Moreover, the
direct correlation between IgG responses in plasma and saliva
suggests that maximizing plasma titers of antibodies that neutralize
rhcmvIL-10 could be reflected by a commensurate increase of
such antibodies in mucosal fluids, perhaps increasing protection
against horizontally transmitted virus. The results herein establish
a framework to measure whether vaccination with non-functional
rhcmvIL-10 stimulates greater level of rhcmvIL-10-specific anti-
body responses above that provided by prior infection with
RhCMV.
Materials and Methods
Ethics statement
The University of California, Davis (UC Davis) is accredited by
the Association for Assessment and Accreditation of Laboratory
Animals Care (AAALAC, Animal Assurance #: A3433-01), a
private, nonprofit group that promotes the humane treatment of
animals in science through voluntary accreditation. UC Davis is
one of more than 640 research institutions and other organizations
that have earned AAALAC accreditation, demonstrating its
commitment to responsible animal care and use. In addition, the
CNPRC receives unannounced inspections by the U.S. Depart-
ment of Agriculture, as required by the Animal Welfare Act, and
inspections by the Food and Drug Administration. This study was
carried out in strict accordance with the recommendations in the
Guide for the Care and Use of Laboratory Animals of the National
Institutes of Health and in accordance with the recommendations
of the Weatherall report, ‘‘The use of nonhuman primates in
research’’. The Institutional Animal Care and Use Committee of
UC Davis approved in advance all animal use protocols. Multiple
veterinarians and animal care technicians provided state-of-the-art
care and research support for these studies. The animals were
monitored by veterinarians and trained animal care staff every day
and during all procedures. Animals were housed in outdoor corrals
(,2,025 square meters) at an average density of 145 macaques per
corral with ages of the animals ranging from neonate to aged adult
(.14 years). Access to water was freely available 24 hours per day,
and fresh food was provided in feeding bins twice each day. Each
corral contained protection from wind, sun, and rain that was
sufficient to protect every animal. Thermostat-controlled heaters
were triggered when the temperature dropped to 2uC during
winter, and thermostat-controlled, overhead water misters were
triggered when the temperature reached 32uC. Electrical systems
were protected by back-up diesel generators in the advent of a
systemic power outage. Animals were anesthetized with ketamine
during blood and saliva collection to prevent any suffering. Care
was taken to ensure that the animals were adequately sedated
under all conditions, as assessed by the veterinarian and/or animal
care staff. The specific animal use protocol for this study was
15137.
Animals
Healthy, genetically outbred rhesus macaques (Macaca mulatta)
from the California National Primate Research Center, confirmed
to be either RhCMV seronegative or RhCMV seropositive, were
used for these studies. Oral swabs were collected according to our
published procedures [73]. The Institutional Animal Care and Use
Committee of the University of California, Davis approved all
animal protocols in advance of any procedures.
Expression and purification of rhcmvIL-10
Purification of wild-type rhcmvIL-10 and the non-functional
versions (M1 and M2) for use in ELISA and in vitro assays has been
previously described [40].
rhcmvIL-10 ELISA
Antibodies against rhcmvIL-10 were characterized by ELISA
by modifying a previously published protocol [74]. Pilot assays
were performed to optimize the amount of coating antigen and
secondary antibody concentration necessary to give a broad linear
range of reactivity and to maximize the distinction between
plasma samples from RhCMV-infected and uninfected animals.
Based on these assays (data not shown), 96-well microplates
(Immulon 4 HBX, Dynex Technologies Inc.) were coated
overnight at 4uC with nickel affinity-purified rhcmvIL-10
(12.5 ng/well) in phosphate buffered saline (PBS) (Sigma)/
0.375% sodium bicarbonate (GIBCO). Each plate was subse-
quently washed 6 times with PBS/0.05% Tween 20 (Sigma) (PBS-
T) and blocked with 300 ml/well PBS/1% bovine serum albumin
(BSA) (Sigma) for 2 hours at 25uC in a temperature-controlled
incubator. After washing the plates 6 times with PBS-T, 100 mlo f
a 1:100 dilution of rhesus monkeys plasma (in PBS-T/1% BSA), or
100 ml of oral swab in PBS (1:10 final dilution) was added to each
well and incubated at 25uC for 2 hours. Plasma samples were from
rhesus macaques serologically confirmed to be infected or
uninfected with RhCMV. Each sample was assayed in duplicate.
The plates were subsequently washed 6 times with PBS-T wash
buffer and loaded with 100 ml/well of a 1:60,000 dilution of
peroxidase-conjugated goat-anti-monkey IgG (Kirkegaard & Perry
Laboratories, Inc - KPL) and incubated at 25uC for 1 hour. The
plates were then washed 6 times with PBS-T wash buffer and
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(Sigma) was added and incubated for 30 min at 25uC. TMB
color development was stopped by the addition of 50 ml/well of
0.5 M sulfuric acid. After a 5-minute incubation at room
temperature, color development was quantified spectrophotomet-
rically at a wavelength of 450 nm on a Model 680 microplate
reader (BioRad). Relative units (RU) were quantified using a
standard curve of 10-fold serial dilutions of plasma from a rhesus
macaque immunized with rhcmvIL-10 [40]. The threshold for a
sample to be considered positive for a specific rhcmvIL-10
antibody response (RU=1) was set at 6 standard deviations above
the control seronegative mean optical density derived from 30
seronegative samples.
Avidity assay of antibodies to rhcmvIL-10
Avidity binding of rhcmvIL-10 antibodies was assayed similarly
to the ELISA protocol, except that after the primary 2-hour
incubation with diluted plasma, the wells were incubated in freshly
prepared 6 M urea for five minutes at room temperature, and then
washed extensively with PBS-T. Secondary goat anti-monkey
antibody was then added for 1 hour, and the plates were washed
and processed for colorimetric development according to the
ELISA protocol. The Avidity Index (AI) was calculated by dividing
the mean optical density of a sample treated with 6 M urea by the
mean optical density of the sample not treated with 6 M urea.
Neutralization of rhcmvIL-10 function in vitro
Plasma samples from RhCMV seropositive and seronegative
macaques were diluted (1:4,000) in RPMI/10% fetal bovine serum
(600 mL final volume) in the presence or absence of recombinant
rhcmvIL-10 (0.5 ng/mL) for 3 hours at 37uC. This dilution of
plasma was necessary due to the presence in plasma of endogenous
inhibitory factors in less dilute plasma that inhibited IL-12
production by activated PBMC. 200 mL of the plasma +/2
rhcmvIL-10 mixtures were then incubated (each in duplicate) with
4610
5 Ficoll-purified PBMC/well in a 96 well U-bottom plate
(Falcon) for 30 minutes in a humidified 37uC incubator (5% CO2).
LPS (from E. coli O127:B8; Sigma) was then added to the cells
(5 mg/mL final concentration), and the cells were then incubated
24 hours at 37uC (5% CO2). The supernatant was collected the
following day and stored at 280uC until assayed for IL-12
production. Rhesus IL-12 secretion by LPS-activated PBMC was
measured by ELISA (U-Cytech, Netherlands), according to the
manufacturer’s protocol with slight variations. Briefly, 96-well
microplates were coated with the supplied IL-12 antibody pair
(p40+p70) and incubated overnight at 4uC. The plates were then
washed 66 with PBS-T and incubated with PBS/1% BSA
blocking buffer for 60 minutes at 37uC. The buffer was removed,
100 mL/well of PBMC supernatant was added, and the cell
mixture was incubated at 4u overnight. The plates were then
washed 6 times with PBS-T wash buffer, 100 mL/well of anti-
monkey ELISA detector antibody was added, and the cells were
incubated 1 hr at 37uC. After washing, 100 mL/well of strepta-
vidin-HR polymer (SPP) conjugate (U-Cytech) was added and
incubated at 37uC for 1 hr. After washing, TMB substrate
(100 mL/well) was added, and the plates were incubated at 25uC
for 11 min. Color development was stopped by the addition of
0.5 M sulfuric acid (50 mL/well). Following a 5-minute incubation
(25uC), the plates were read at a wavelength of 450 nm on a
Model 680 microplate reader (BioRad). Concentrations of IL-12
were quantified using a 2-fold serially diluted recombinant IL-12
standard (U-Cytech) that was included on each plate. Neutraliza-
tion was calculated as the inverse of the ratio of (IL-12
concentration+rhcmvIL-10+plasma)/(IL-12 concentration+-
plasma only) and was expressed as the ‘‘percent (%) IL-12
induction restored’’.
PBMC immunostaining
To evaluate T-cell responses to rhcmvIL-10, cryogenially
preserved PBMC were thawed and rested overnight at 37u in
complete RPMI medium containing 10% endotoxin-free FCS,
2 mM L-glutamine, 100 U/mL penicillin, 100 mg/mL strepto-
mycin, 50 mM 2-mercaptoethanol, and 10 mM Hepes and stained
following our published protocol [20] with slight modifications.
Briefly, PBMC (2.5610
6 cells/mL in 48-well plates) were treated
with either heat-inactivated RhCMV virion (10.0 mg/mL), non-
functional rhcmvIL-10 proteins rhcmvIL-10M1 and rhcmvIL-
10M2 (5.0 mg/mL each), or media only in the presence of co-
stimulatory monoclonal antibodies to CD28 (clone 28.2) and
CD49d (clone 9F10) (5 mg/mL each; ebiosciences) for 6.5 hours
with the addition of Golgistop and Golgiplug after the first
1.5 hours. Surface staining was done using directly conjugated
monoclonal antibodies against human (rhesus-macaques cross-
reactive) CD3 (clone SP34-2), CD4 (clone L200) and CD8 (Clone
SK1) (BD Biosciences). Cells were then fixed, permeabalized using
the Fixation/Permeabilization Kit (BD Biosciences) and stained
internally for IFN-c (clone 4S.B3; BD Biosciences). A background
baseline value was established for each animal by running a
parallel sample without antigen stimulation. This value was the
subtracted from the corresponding antigen stimulated sample.
Flow Cytometry
Four-color flow cytometry was performed using the FACSCa-
libur with CellQuest software (BD Biosciences). Results were
analyzed and displayed using FlowJo software (Tree Star).
Statistics
All ELISA based OD results were converted into IgG relative
units using a log-log regression model equation. The statistical
analysis program Prism 4 was used for all statistical analyses. All
corral surveys for the presence of RhCMV and rhcmvIL-10
antibodies were analyzed using the student’s t-test (/=0.05). All
significant correlations were determined using Pearson’s correla-
tion coefficient analysis. One-way ANOVA and Kruskal-Wallis
test with Dunn’s Multiple Comparison (/=0.05) were used for all
age-matched analyses.
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